Evidence map›Paper›PMID 40382362›Full record

ArticleNPJ vaccines2025

Durable T cell immunity to COVID-19 vaccines in MS patients on B cell depletion therapy.

Julia Davis-Porada, Ceren Tozlu, Claudia Aiello, Sokratis A Apostolidis, Amit Bar-Or, Riley Bove, Diego A Espinoza, Sugeidy Ferreira Brito, Dina Jacobs, Mihir Kakara and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Julia Davis-PoradaDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.
Ceren TozluDepartment of Radiology, Weill Cornell Medicine, New York, NY, USA.
Claudia AielloDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.
Sokratis A ApostolidisInstitute for Immunology and Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Amit Bar-OrCenter for Neuroinflammation and Experimental Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Riley BoveUCSF Weill Institute for Neuroscience, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Diego A EspinozaCenter for Neuroinflammation and Experimental Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Sugeidy Ferreira BritoDepartment of Neurology, Columbia University Vagelos College of Physicians and Surgeons, Neurology, Columbia Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, New York, NY, USA.
Dina JacobsCenter for Neuroinflammation and Experimental Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Mihir KakaraDepartment of Neurology, NYU Grossman School of Medicine, New York, NY, USA.
Kaho OnomichiDepartment of Neurology, Columbia University Vagelos College of Physicians and Surgeons, Neurology, Columbia Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, New York, NY, USA.
Adelle RicciDepartment of Neurology, Columbia University Vagelos College of Physicians and Surgeons, Neurology, Columbia Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, New York, NY, USA.
Joseph J SabatinoUCSF Weill Institute for Neuroscience, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Elizabeth WalkerDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.
E John WherryInstitute for Immunology and Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Lili ZhangDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.
Wen ZhuDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.
Zongqi XiaDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.
Philip De JagerDepartment of Neurology, Columbia University Vagelos College of Physicians and Surgeons, Neurology, Columbia Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, New York, NY, USA.
Sarah Flanagan Wesley *Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, Neurology, Columbia Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, New York, NY, USA. sfw2116@cumc.columbia.edu.
Rebecca Straus Farber *Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, Neurology, Columbia Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, New York, NY, USA. rs3648@cumc.columbia.edu.
Donna L Farber *Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA. df2396@cumc.columbia.edu.

Funding

Viral Assays CoreU19AI128949 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Donna L. Farber, Peter Alan Sims · 2017 to 2026
$26.4M
Medical Scientist Training ProgramT32GM145440 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI STEVEN L REINER · 2022 to 2026
$7.3M
Leveraging electronic health records to optimize treatment selection and response in multiple sclerosisR01NS098023 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Zongqi Xia · 2016 to 2026
$4.6M
The generation and protective function of lung tissue resident memory T cells following SARS-CoV-2 infection or vaccinationR01AI167372 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Donna L. Farber, John Ross Teijaro · 2022 to 2026
$4.4M
Real-world impact of the COVID-19 pandemic in people with multiple sclerosisR01NS124882 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI XIA, ZONGQI · 2022 to 2024
$1.2M
Five-laser Aurora spectral flow cytometerS10OD030282 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CREUSOT, REMI J · 2022 to 2022
$361k
National Institute of Allergy and Infectious Diseases F30AI74785National Institute of Allergy and Infectious Diseases U19AI128949National Multiple Sclerosis Society TA-2204-39428NIAID NIH HHS R01 AI167372NIAID NIH HHS U19 AI128949NIGMS NIH HHS T32 GM145440NIH HHS S10 OD030282NINDS NIH HHS R01 NS098023NINDS NIH HHS R01 NS124882Novartis Pharmaceuticals Corporation COMB157GUS20T
6 · The paper itself

Abstract

Immune-mediated protection generated to COVID-19 mRNA vaccines is associated with anti-Spike (S) protein neutralizing antibodies. However, humoral immunity is compromised in B cell depleting (BCD) therapies, used to treat autoimmune diseases such as Multiple Sclerosis (MS). To study the effect of BCD on the durability and protective efficacy of vaccine-induced immunity, we evaluated S-reactive antibodies and T cell responses 1-70 weeks post-vaccination in MS cohorts treated with BCD compared to non-BCD therapies from four centers. BCD-treated participants had significantly reduced antibody levels and enhanced frequencies of S-reactive CD4

Identifiers

PMID40382362
PMCPMC12085558

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.